The efficacy of interleukin-6 inhibitor tocilizumab for takayasu’s arteritis, after insufficient response to previous treatment with glucocorticoids, methotrexate, cyclophosphamide, fludarabine. (A case report)
https://doi.org/10.47360/1995-4484-2020-743-746
Abstract
Thanks to progress in understanding of Takayasu’s arteritis pathogenesis, the role of biological therapies is expanding, especially in refractory diseases. Robust data are still lacking to draw conclusions concerning the use of interleukin (IL)-6 inhibitors in Takayasu’s arteritis. The article presents own experience of the use of tocilizumab (TCZ) for Takayasu’s arteritis after insufficient response to previous treatment with glucocorticoids, methotrexate, cyclophosphamide, fludarabine and intolerance of cyclophosphamide, glucocorticoids. As result of TCZ treatment (600 mg IV every 4 weeks for 24 months), a stable Takayasu’s arteritis remission was achieved and confirmed by fluorodeoxyglucose-positron emission tomography.
The inhibition of IL-6 can be considered as a promising innovative strategy for the treatment of Takayasu’s arteritis, primarily with insufficient response, intolerance or contraindications to standard therapy.
About the Authors
V. N. Antipova
National Research Ogarev Moldovia State University
Russian Federation
Competing Interests: not
Russian Federation
Valentina N. Antipova
430005, Saransk, Bolshevistskaya str., 68, Republic of Mordovia
Competing Interests: not
L. V. Solodovnikova
Mordovia Republican Central Clinical Hospital
Russian Federation
Competing Interests: not
Russian Federation
Larisa V. Solodovnikova
430013, Saransk, Pobedy str., 14/5, building 1, Republic of Mordovia
Competing Interests: not
T. V. Beketova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests: not
Russian Federation
Tatiana V. Beketova
115522, Moscow, Kashirskoye Highway, 34A
Competing Interests: not
References
1. Nakaoka Y, Isobe M, Takei S, Tanaka E, Ishii T, Yokota S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018;77(3):348-354. DOI: 10.1136/annrheum-dis-2017-211878
2. Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol. 2017;69(4):846-853. DOI: 10.1002/art.40037
3. Agueda AF, Monti S, Luqmani RA, Buttgereit F, Cid M, Dasgupta B, et al. Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. RMD Open. 2019;5(2):e001020. DOI: 10.1136/rmdopen-2019-001020
4. Pokrovskii AV, Zotikov AE, Yudin VI. Nespetsificheskiy aortoar-teriit (bolezn’ Takayasu) [Nonspecific aortoarteritis (Takayasu’s disease)]. Moscow: IRSIS; 2002 (In Russian).
5. Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z. Pathogenesis of Takayasu’s arteritis: A 2011 update. Autoimmun Rev. 2011;11(1):61-67. DOI: 10.1016/j.autrev.2011.08.001
6. Elefante E, Bond M, Monti S, Lepri G, Cavallaro E, Felicetti M, et al. One year in review 2018: Systemic vasculitis. Clin Exp Rheumatol. 2018;36 Suppl 111(2):12-32.
7. Arraes AED, de Souza AWS, Mariz HA, Silva NP, Torres ICG, Pinto PNV, et al. 18F-Fluorodeoxyglucose positron emission tomography and serum cytokines and matrix metalloproteinases in the assessment of disease activity in Takayasu’s arteritis. Rev Bras Reumatol. 2015; S0482-5004(15)00093-5. DOI: 10.1016/j.rbr.2015.03.009
8. Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatology. 2006;45(5):545-548. DOI: 10.1093/rheumatology/kei266
9. Kong X, Sun Y, Ma L, Chen H, Wei L, Wu W, et al. The critical role of IL-6 in the pathogenesis of Takayasu arteritis. Clin Exp Rheumatol. 2016;34(3 Suppl 97):S21-27.
10. Alibaz-Oner F, Yentur SP, Saruhan-Direskeneli G, Direskeneli H. Serum cytokine profiles in Takayasu’s arteritis: search for biomarkers. Clin Exp Rheumatol. 2015;33(2 Suppl 89):32-35.
11. Hoffman GS. Treatment of resistant Takayasu’s arteritis. Rheum Dis Clin North Am. 1995;21(1):73-80.
12. Ohigashi H, Tamura N, Ebana Y, Harigai M, Maejima Y, Ashikaga T, et al. Effects of immunosuppressive and biological agents on refractory Takayasu arteritis patients unresponsive to glucocorticoid treatment. J Cardiol. 2017;69(5):774-778. DOI: 10.1016/j.jjcc.2016.07.009
13. Gorodetsky VR, Vasilyev VI, Sedyshev SK, Ogorodnikova MD, Bozh’eva LA, Nasonov EL. Pervyj opyt ispol’zovanija fludarabina v lechenii pacienta s refrak-ternym techeniem granulematoza Vegenera [The first experience with fludarabine used to treat a patient with refractory Wegener’s granulomatosis] Rheumatology Science and Practice. 2012;50(2):76-80. (In Russian). DOI: 10.14412/1995-4484-2012-1277
14. Mekinian A, Comarmond C, Resche-Rigon M, Mirault T, Kahn JE, Lambert M, et al. Efficacy of biological-targeted treatments in Takayasu arteritis: Multicenter, retrospective study of 49 patients. Circulation. 2015;132(18):1693-1700. DOI: 10.1161/CIRCULATIONAHA.114.014321
15. Goel R, Danda D, Kumar S, Joseph G. Rapid control of disease activity by tocilizumab in 10 ‘difficult-to-treat’ cases of Takayasu arteritis. Int J Rheum Dis. 2013;16(6):754-761. DOI: 10.1111/1756-185X.12220
16. Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: Long-term follow-up. Ann Rheum Dis. 2008;67 (11):1567-1569. DOI: 10.1136/ard.2008.093260
17. Comarmond C, Plaisier E, Dahan K, Mirault T, Emmerich J, Amoura Z, et al. Anti TNF-alpha in refractory Takayasu’s arteritis: Cases series and review of the literature. Autoimmun Rev. 2012;11(9):678-684. DOI: 10.1016/j.autrev.2011.11.025
18. Tombetti E, Baldissera E, Franchini S, Motta F, Aiello P, Cavalli G, et al. THU0209 Efficacy of anti-TNF therapy in 15 patients with refractory takayasu’s arteritis: Long term unicentric follow-up. Ann Rheum Dis. 2013;71:226.
19. Park EH, Lee EY, Lee YJ, Ha YJ, Wan-Hee Y, Choi BY, et al. Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study. Rheumatol Int. 2018;38(12):2233-2242. DOI: 10.1007/s00296-018-4159-1
20. Zhou J, Chen Z, Li J, Yang Y, Zhao J, Chen H, et al. The efficacy of tocilizumab for the treatment of Chinese Takayasu’s arteritis. Clin Exp Rheumatol. 2017;35 Suppl 103(1):171-175.
21. Novikov PI, Smitienko IO, Sokolova MV, Moiseev SV. Certolizumaba pjegol v lechenii arteriita Takajasu: pervyj opyt i perspektivy [Certolizumab pegol in the treatment of Takayasu arteritis: the first experience and prospects]. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):333-338 (In Russian). DOI: 10.14412/1995-44842018-333-338
22. Canas C, Canas F, Izquierdo J, Echeverri AF, Mejia M, Bonilla-Abadia F, et al. Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis. J Clin Rheumatol. 2014;20(3):125-129. DOI: 10.1097/RHU.0000000000000098
23. Beketova TV, Nasonov EL. Innovacionnye metody lechenija arteriita Takajasu: v fokuse ingibitory interlejkina 6. Sobstvennyj opyt primenenija tocilizumaba i obzor literatury [Innovative treatments for Takayasu’s arteritis: a focus on interleukin-6 inhibitors. The authors’ experience with tocilizumab and a review of literature]. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(5):536-548. (In Russian). DOI: 10.14412/1995-4484-2017-536-548
24. Salvarani C, Magnani L, Catanoso MG, Pipitone N, Versari A, Dardani L, et al. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-a blockers. Clin Exp Rheumatol. 2012;30(Suppl 70):S90-93.
25. Campochiaro C, Tomelleri A, Sartorelli S, Cavalli G, De Luca G, Baldissera E, et al. Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. Semin Arthritis Rheum. 2020;50(3):509-514. DOI: 10.1016/j.semarthrit.2020.01.005
26. De Kruif M, van Gorp E, Bel E, Gerlag DM, Kunst PW. Streptococcal lung abscesses from a dental focus following tocili-zumab: A case report. Clin Exp Rheumatol. 2012;30(6):951-953.
27. Xenitidis T, Horger M, Zeh G, Kanz L, Henes JC. Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. Rheumatology (Oxford). 2013;52(9):1729-1731. DOI: 10.1093/rheumatology/ket107
28. Youngstein T, Peters J, Hamdulay S, Mewar D, Price-Forbes A, Lloyd M, et al. Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-alpha and IL-6 receptor targeted therapies in refractory Takayasu arteritis. Clin Exp Rheumatol. 2014;32(3 Suppl 82):S11-18.
Review
For citations:
Antipova V.N., Solodovnikova L.V., Beketova T.V. The efficacy of interleukin-6 inhibitor tocilizumab for takayasu’s arteritis, after insufficient response to previous treatment with glucocorticoids, methotrexate, cyclophosphamide, fludarabine. (A case report). Rheumatology Science and Practice. 2020;58(6):743-746. (In Russ.) https://doi.org/10.47360/1995-4484-2020-743-746
Views:
604
Email this article 